Nephropathy | Nephrologist expert commentary: The CREDENCE trial | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

17-04-2019 | Nephropathy | Podcast | Article

Nephrologist expert commentary: The CREDENCE trial

Andrew Frankel, Consultant Physician and Nephrologist at Imperial College Healthcare NHS Trust, tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

This podcast is also available on... | Direct download

Medicine Matters Diabetes

Nephrologist expert commentary: The CREDENCE trial

More content in this series

New additions to the Adis Journal Club

ADA 2022 coverage

Related content

SONAR results support atrasentan for preserving renal function in type 2 diabetes

Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

Diabetic kidney disease: A call to primary care

Medicine Matters Diabetes

External Content

More content in this series

New additions to the Adis Journal Club

ADA 2022 coverage

Related content

SONAR results support atrasentan for preserving renal function in type 2 diabetes

Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

Diabetic kidney disease: A call to primary care